BACKGROUND: The purpose of the current study was to describe a population of young patients with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival. METHODS: Four hundred fifty-two women age < or = 35 years with breast carcinoma were registered at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between 1990 and 2002. The relation between clinicopathologic factors and disease recurrence-free survival (RFS) and overall survival (OS) was assessed. Cox regression analysis was used to identify independent survival predictors. RESULTS: The median age of the patients was 32 years. Most of the patients were white, and 20% were obese. Approximately 50% reported oral contraceptive use, 34% reported a family history of breast carcinoma, and 5% reported a family history of ovarian carcinoma. Sixty-nine percent of tumors were nuclear Grade 3 (using the modified Black's nuclear grading system), 52% had positive estrogen receptors, and 48% had positive progesterone receptors. HER-2/neu status was available in 60% of tumor specimens and 34% were HER-2/neu positive. The median follow-up was 36 months. There were 185 disease recurrences and 84 deaths. RFS was significantly shorter in patients who reported a family history of ovarian carcinoma (P < 0.0001) and in those who had hormone receptor-negative tumor specimens (P = 0.001). OS was significantly shorter in patients who reported a family history of ovarian carcinoma (P = 0.001), those who had hormone receptor-negative tumor specimens (P < 0.0001), or those with > nuclear Grade 3 tumor specimens (P = 0.005). CONCLUSIONS: This young population with breast carcinoma was found to have more aggressive biologic features. Hormone receptor negativity and a family history of ovarian carcinoma were associated with shorter RFS and OS. Copyright 2005 American Cancer Society.
BACKGROUND: The purpose of the current study was to describe a population of young patients with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival. METHODS: Four hundred fifty-two women age < or = 35 years with breast carcinoma were registered at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between 1990 and 2002. The relation between clinicopathologic factors and disease recurrence-free survival (RFS) and overall survival (OS) was assessed. Cox regression analysis was used to identify independent survival predictors. RESULTS: The median age of the patients was 32 years. Most of the patients were white, and 20% were obese. Approximately 50% reported oral contraceptive use, 34% reported a family history of breast carcinoma, and 5% reported a family history of ovarian carcinoma. Sixty-nine percent of tumors were nuclear Grade 3 (using the modified Black's nuclear grading system), 52% had positive estrogen receptors, and 48% had positive progesterone receptors. HER-2/neu status was available in 60% of tumor specimens and 34% were HER-2/neu positive. The median follow-up was 36 months. There were 185 disease recurrences and 84 deaths. RFS was significantly shorter in patients who reported a family history of ovarian carcinoma (P < 0.0001) and in those who had hormone receptor-negative tumor specimens (P = 0.001). OS was significantly shorter in patients who reported a family history of ovarian carcinoma (P = 0.001), those who had hormone receptor-negative tumor specimens (P < 0.0001), or those with > nuclear Grade 3 tumor specimens (P = 0.005). CONCLUSIONS: This young population with breast carcinoma was found to have more aggressive biologic features. Hormone receptor negativity and a family history of ovarian carcinoma were associated with shorter RFS and OS. Copyright 2005 American Cancer Society.
Authors: Serena Masciari; Deborah A Dillon; Michelle Rath; Mark Robson; Jeffrey N Weitzel; Judith Balmana; Stephen B Gruber; James M Ford; David Euhus; Alexandra Lebensohn; Melinda Telli; Stephen M Pochebit; Georgios Lypas; Judy E Garber Journal: Breast Cancer Res Treat Date: 2012-03-04 Impact factor: 4.872
Authors: Rachel L Theriault; Jennifer K Litton; Elizabeth A Mittendorf; Huiqin Chen; Funda Meric-Bernstam; Mariana Chavez-Macgregor; Phuong K Morrow; Wendy A Woodward; Aysegul Sahin; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Clin Breast Cancer Date: 2011-07-20 Impact factor: 3.225
Authors: Denae W King; Theresa M Duello; Patricia Y Miranda; Kelly P Hodges; Andrea J Shelton; Paul Chukelu; Lovell A Jones Journal: J Womens Health (Larchmt) Date: 2010-05 Impact factor: 2.681
Authors: Mustafa Emiroğlu; Cem Karaali; İsmail Sert; Semra Salimoğlu; Levent Uğurlu; Süleyman Aksoy; Cengiz Aydın Journal: J Breast Health Date: 2015-07-01